Skip to main content

DNA copy number changes in breast cancer samples using array-CGH profiling

Discovering DNA copy number alterations is a major goal in studying susceptibility and the cause of diseases such as cancer. Agilent Technologies' whole genome comparative genomic hybridization array (aCGH) together with highly optimized reagents and protocols are used to generate genome-wide profiles of cancers to help in the identification of causative, diagnostic and prognostic changes. The comparison of the aCGH profile from the breast cancer tumor primary cell line with the aCGH profile of EBV-transformed peripheral blood from the same breast cancer patient showed several regions of DNA loss and gain. These regions were confirmed to correlate with the disease on a panel of flash-frozen breast cancer tumor samples. Using Agilent Technologies' CGHAnalytics software, candidate genes and ESTs have been identified for these regions of interest. Further studies on large breast cancer patient cohorts are required to see whether these candidate genes and ESTs are causative and would have profound prognostic implications.

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Argonza-Barrett, R., Dorlijn, W. & Bailey, J. DNA copy number changes in breast cancer samples using array-CGH profiling. Breast Cancer Res 7, P4.41 (2005).

Download citation

  • Published:

  • DOI:


  • Copy Number Change
  • Comparative Genomic Hybridization Array
  • Copy Number Alteration
  • Breast Cancer Tumor
  • Tumor Primary Cell